Restricted accessResearch articleFirst published online 2014-05
Efficacy and Safety of Trastuzumab-based Therapy in Combination with Different Chemotherapeutic Regimens in Advanced Esophagogastric Cancer – a Single Cancer-center Experience
Trastuzumab-based therapy has significantly changed the management of Her-2 positive metastatic esophagogastric cancer. However, only limited experience exists for the management in patients who are not suitable for cisplatin-based therapy.
Methods
Patients treated with trastuzumab in combination with different chemotherapeutic regimens were analyzed. Response rates, progression-free survival, overall survival, patterns of cardiac toxicity and patterns of maintenance strategies were recorded.
Results
The response rates, progression-free survival and overall survival in patients with metastatic esophagogastric cancer treated with trastuzumab and different chemotherapeutic regimens compared well with the data published in the TOGA trial. No unexpected toxicity occurred. Different strategies were used for therapy de-escalation.
Conclusion
Trastuzumab-based therapy is effective in combination with several chemotherapeutic regimens with a safe toxicity pattern. The optimal maintenance strategy remains to be defined.
FerlayJ., ShinH.R., BrayF., FormanD., MathersC., ParkinD.M.: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127: 2893–2917, 2010.
2.
PowellJ., McConkeyC.C.: Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer, 62: 440–443, 1990.
3.
WagnerA.D., GrotheW., HaertingJ., KleberG., GrotheyA., FleigW.E.: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol, 24: 2903–2909, 2006.
4.
Van CutsemE., MoiseyenkoV.M., TjulandinS., MajlisA., ConstenlaM., BoniC., RodriguesA., FodorM., ChaoY., VoznyiE., RisseM.L., AjaniJ.A.; V325 Study Group: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol, 24: 4991–4997, 2006.
5.
CunninghamD., StarlingN., RaoS., IvesonT., NicolsonM., CoxonF., MiddletonG., DanielF., OatesJ., NormanA.R.; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med, 358: 36–46, 2008.
6.
GravalosC., JimenoA.: HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol, 19: 1523–1529, 2008.
7.
HofmannM., StossO., ShiD., BüttnerR., van de VijverM., KimW., OchiaiA., RüschoffJ., HenkelT.: Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology, 52: 797–805, 2008.
8.
TannerM., HollménM., JunttilaT.T., KapanenA.I., TommolaS., SoiniY., HelinH., SaloJ., JoensuuH., SihvoE., EleniusK., IsolaJ.: Amplification of HER-2 in gastric carcinoma: association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol, 16: 273–278, 2005.
9.
KunzP.L., MojtahedA., FisherG.A., FordJ.M., ChangD.T., BaliseR.R., BangsC.D., CherryA.M., PaiR.K.: HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol, 20: 13–24, 2012.
10.
JanjigianY.Y., WernerD., PauligkC., SteinmetzK., KelsenD.P., JägerE., AltmannsbergerH.M., RobinsonE., TafeL.J., TangL.H., ShahM.A., Al-BatranS.E.: Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA international collaborative analysis. Ann Oncol, 23: 2656–2662, 2012.
11.
BangY.J., Van CutsemE., FeyereislovaA., ChungH.C., ShenL., SawakiA., LordickF., OhtsuA., OmuroY., SatohT., AprileG., KulikovE., HillJ., LehleM., RüschoffJ., KangY.K.; ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 376: 687–697, 2010.
12.
DaiG.H., ShiY., ChenL., LvY.L., ZhongM.: Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression. Hepatogastroenterology, 59: 2439–2444, 2012.
13.
WeissingerF., ReymondM., DumkeK., KrügerM.: Successful treatment of a patient with HER2-positive metastatic gastric cancer with third-line combination therapy with irinotecan, 5-fluorouracil, leucovorin and trastuzumab (FOLFIRI-T). Onkologie, 34: 548–551, 2011.
14.
Al-BatranS.E., RuppertM., JägerE.: Trastuzumab plus chemotherapy in gastric cancer overexpressing HER-2 and EGFR: a case report. Onkologie, 34: 42–45, 2011.
15.
Al-BatranS.E., HartmannJ.T., ProbstS., SchmalenbergH., HollerbachS., HofheinzR., RethwischV., SeipeltG., HomannN., WilhelmG., SchuchG., StoehlmacherJ., DerigsH.G., Hegewisch-BeckerS., GrossmannJ., PauligkC., AtmacaA., BokemeyerC., KnuthA., JägerE.; Arbeitsgemeinschaft Internistische Onkologie: Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol, 26: 1435–1442, 2008.
16.
Al-BatranS.E., HartmannJ.T., HofheinzR., HomannN., RethwischV., ProbstS., StoehlmacherJ., ClemensM.R., MahlbergR., FritzM., SeipeltG., SievertM., PauligkC., AtmacaA., JägerE.: Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol, 19: 1882–1887, 2008.
17.
KangY.K., KangW.K., ShinD.B., ChenJ., XiongJ., WangJ., LichinitserM., GuanZ., KhasanovR., ZhengL., Philco-SalasM., SuarezT., SantamariaJ., ForsterG., McCloudP.I.: Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol, 20: 666–673, 2009.
18.
LeeJ.L., RyuM.H., ChangH.M., KimT.W., YookJ.H., OhS.T., KimB.S., LeeJ.S., KangY.K.: Efficacy and safety study of docetaxel as salvage chemotherapy in metastatic gastric cancer failing fluoropyrimidine and platinum combination chemotherapy. Cancer Res Treat, 37: 201–207, 2005.
19.
DongN., JiangW., LiH., LiuZ., XuX., WangM.: Triweekly oxaliplatin plus oral capecitabine as first-line chemotherapy in elderly patients with advanced gastric cancer. Am J Clin Oncol, 32: 559–563, 2009.
20.
HongY.S., SongS.Y., LeeS.I., ChungH.C., ChoiS.H., NohS.H., ParkJ.N., HanJ.Y., KangJ.H., LeeK.S., ChoJ.Y.: A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol, 15: 1344–1347, 2004.
21.
Al-BatranS.E., HozaeelW., JägerE.: Combination of trastuzumab and triple FLOT chemotherapy (5-fluorouracil/leucovorin, oxaliplatin, and docetaxel) in patients with HER2-positive metastatic gastric cancer: report of 3 cases. Onkologie, 35: 505–508, 2012.
22.
Hegewisch-BeckerS., MoorahrendE., KröningH., PetersenV., HannigC., PottD., TirierC., LerchenmullerC.A., SchlagR., Schneider-KappusW., KaecheleV., Al-BatranS.E.: Trastuzumab (TRA) in combination with different firstline chemotherapies for treatment of HER2-positive metastatic gastric or gastroesophageal junction cancer (MGC): findings from the German noninterventional observational study HerMES. J Clin Oncol, 30(suppl; abstr 4065): 2012.
